Duovir Tablet (Lamivudine 150mg + Zidovudine 300mg)

What is Duovir Tablet (Lamivudine 150mg + Zidovudine 300mg)?

Duovir Tablet is a fixed-dose combination medication containing Lamivudine 150mg and Zidovudine 300mg, two nucleoside reverse transcriptase inhibitors (NRTIs) used in the management of human immunodeficiency virus (HIV) infection. It is not a cure for HIV but helps reduce viral load and improve immune function when used as part of a complete antiretroviral regimen. This tablet simplifies dosing by combining two essential medications into a single pill, typically taken twice daily under medical supervision.

Key features

• Dual NRTI Combination — Contains Lamivudine and Zidovudine in optimized doses for synergistic antiviral effect.
• Oral Tablet Form — Easy-to-swallow tablet for twice-daily administration.
• HIV-1 Suppression — Helps lower viral load and delay disease progression.
• Manufactured to Quality Standards — Produced under strict pharmaceutical controls for consistency and safety.
• Prescription-Based Use — Intended for use under the guidance of a qualified healthcare provider.
• Part of Combination Therapy — Must be used with other antiretrovirals, not as monotherapy.
• Stable at Room Temperature — No refrigeration required, enhancing storage convenience.

Who is Duovir Tablet (Lamivudine 150mg + Zidovudine 300mg) for?

This medication is intended for adults and pediatric patients (based on weight and clinical assessment) diagnosed with HIV-1 infection. It is prescribed as part of a multi-drug regimen and is not suitable for individuals with hypersensitivity to either active ingredient or those with severe anemia or neutropenia. Patients with liver or kidney impairment should use it cautiously.

How does Duovir Tablet (Lamivudine 150mg + Zidovudine 300mg) compare?

Compared to taking Lamivudine and Zidovudine as separate tablets, Duovir improves adherence by reducing pill burden. It offers similar efficacy to other dual NRTI combinations but may carry a higher risk of hematologic side effects than newer agents like tenofovir-based regimens. It remains a cost-effective option in resource-limited settings but is less commonly used in regions favoring newer, better-tolerated antiretrovirals.